-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SW6oeROptnzofyYGf58XSvwJRYQ0ujDeWbKQbR8U7TGoKMWwfoPb6HwIPzdPoSHN ZiMNthgdKbyJB/uLLPBYyw== 0001000228-08-000022.txt : 20080805 0001000228-08-000022.hdr.sgml : 20080805 20080805082416 ACCESSION NUMBER: 0001000228-08-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080617 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080805 DATE AS OF CHANGE: 20080805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HENRY SCHEIN INC CENTRAL INDEX KEY: 0001000228 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 113136595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1226 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27078 FILM NUMBER: 08989727 BUSINESS ADDRESS: STREET 1: 135 DURYEA RD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 6318435500 MAIL ADDRESS: STREET 1: 135 DURYEA RD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: SCHEIN HENRY INC DATE OF NAME CHANGE: 19950907 8-K 1 the8k.txt COVER PAGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2008 ------------------- HENRY SCHEIN, INC. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) DELAWARE 0-27078 11-3136595 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) Identification No.) 135 DURYEA ROAD, MELVILLE, NEW YORK 11747 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (631) 843-5500 ----------------- NOT APPLICABLE - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02. Results of Operations and Financial Condition. On August 5, 2008, Henry Schein, Inc. issued a press release reporting the financial results for the three and six months ended June 28, 2008. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (a) Not applicable. (b) Not applicable. (c) Not applicable. (d) Exhibit 99.1 - Press Release dated August 5, 2008. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HENRY SCHEIN, INC. By: /s/ Steven Paladino ------------------------------------ Steven Paladino Executive Vice President and Chief Financial Officer (principal financial and accounting officer) August 5, 2008 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release dated August 5, 2008. EX-99 2 exh99.txt EXHIBITS HENRY SCHEIN NEWS RELEASE Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747 FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS RECORD SECOND QUARTER RESULTS Sales increase 19% to $1.6 billion Diluted EPS from continuing operations up 18% to $0.71 MELVILLE, N.Y. - August 5, 2008 - Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported record financial results for the quarter ended June 28, 2008. Net sales for the second quarter of 2008 were $1.6 billion, an increase of 18.6% compared with the second quarter of 2007. This increase includes 13.6% local currency growth (4.0% internally generated and 9.6% from acquisitions) and 5.0% related to foreign currency exchange. (See Exhibit A for details of sales growth.) The Company previously announced an initiative of reducing sales of certain lower-margin pharmaceutical products. Excluding sales of those products, internal net sales growth in local currencies was 6.6%. Income from continuing operations for the second quarter of 2008 was $65.5 million, or $0.71 per diluted share, up 20.3% and 18.3%, respectively, compared with the prior-year second quarter. There was no impact from discontinued operations on our 2008 results. "Second quarter financial results reflect a strong contribution from our International Group, as well as solid growth in our Dental Group," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "These results illustrate Henry Schein's ability to deliver consistent sales and earnings growth." Dental Group sales of $660 million increased 9.7%, including 8.7% growth in local currencies (7.2% internally generated and 1.5% from acquisitions) and 1.0% growth related to foreign currency exchange. Of the 8.7% local currency growth, Dental consumable merchandise sales increased 7.9% (6.3% internal growth and 1.6% acquisition growth) and Dental equipment sales and service revenues were up 11.0% (9.9% internal growth and 1.1% acquisition growth). "Our Dental Group continues to gain market share in consumable merchandise and in equipment," commented Mr. Bergman. "We recorded another quarter of double-digit growth in equipment sales and service revenues, highlighted by gains in high-tech products, including acceleration in sales of the E4D CAD/CAM product compared with the first quarter." Medical Group sales of $329 million declined 8.3% (8.9% decline in internal growth and 0.6% acquisition growth). Excluding sales of certain lower- margin pharmaceutical products, noted above, internal Medical Group net sales growth was approximately 1%. "With the progress we have made under the Medical One World initiative, coupled with the growth we have seen in Privileges enrollment, we look forward to capitalizing on future sales growth opportunities within our Medical Group," said Mr. Bergman. "We are also optimistic about the upcoming influenza vaccine season, based on current market conditions and customer order activity." For the quarter, International Group sales of $615 million increased 55.7%, including 39.7% growth in local currencies (10.9% internally generated and 28.8% from acquisitions) and 16.0% related to foreign currency exchange. "Our International Group reported strong growth in all major markets, highlighted by solid Dental growth," added Mr. Bergman. "We are also pleased to report that W. & J. Dunlop continues to perform above expectations." Technology and Value-Added Services Group sales of $41 million increased 29.0%, including 28.6% growth in local currencies (1.8% internally generated and 26.8% acquisition growth) and 0.4% growth related to foreign currency exchange. "Results reflect good growth in electronic and financial services, as well as last year's acquisition of Software of Excellence, a leading supplier of innovative clinical and practice management solutions to dentists," stated Mr. Bergman. "During the second quarter we launched Easy Dental 2008, offering dentists increased functionality and improved productivity." Year-to-Date Results For the first six months of 2008, net sales of $3.2 billion represent an increase of 17.6% compared with the first six months of 2007. This increase includes 12.8% local currency growth (3.5% internally generated and 9.3% from acquisitions) and 4.8% related to foreign currency exchange. Excluding sales of certain lower-margin pharmaceutical products, noted above, internal net sales growth was 6.0%. Income from continuing operations for the first six months of 2008 was $117.8 million, reflecting 20.4% growth compared with the prior year. Earnings per diluted share from continuing operations of $1.28 for the first six months of 2008 represents 18.5% growth over the comparable period in 2007. 2 -more- Stock Repurchase Plan Henry Schein announced that it repurchased 602,000 shares of common stock during the second quarter of 2008 for a total purchase price of nearly $32 million. Approximately $109 million remains authorized for future common stock repurchases. The impact of the share repurchases during the quarter was immaterial to diluted EPS. 2008 EPS Guidance Henry Schein affirms 2008 financial guidance, as follows: o 2008 diluted EPS is expected to be $2.93 to $3.00, representing growth of 14% to 16% compared with 2007. o This 2008 diluted EPS guidance includes Henry Schein's expectation that it will distribute 12 million to 15 million doses of influenza vaccine during the year, representing earnings of $0.13 to $0.16 per diluted share. o 2008 diluted EPS guidance is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. Second Quarter Conference Call Webcast The Company will hold a conference call to discuss second quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended. About Henry Schein Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 550,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. 3 - more - The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private- brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an installed user base of more than 52,000 practices, including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics. Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 20 countries. The Company's net sales reached a record $5.9 billion in 2007. For more information, visit the Henry Schein Web site at www.henryschein.com. In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward- looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward- looking statements. 4 - more - (TABLES TO FOLLOW) HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data) (unaudited)
Three Months Ended Six Months Ended ----------------------------- ----------------------------- June 28, June 30, June 28, June 30, 2008 2007 2008 2007 ------------- ------------- ------------- ------------- Net sales .................................................... $ 1,644,977 $ 1,387,017 $ 3,170,596 $ 2,697,145 Cost of sales ................................................ 1,156,562 973,240 2,230,948 1,892,322 ------------- ------------- ------------- ------------- Gross profit .......................................... 488,415 413,777 939,648 804,823 Operating expenses: Selling, general and administrative ...................... 375,058 322,925 741,064 640,250 ------------- ------------- ------------- ------------- Operating income ...................................... 113,357 90,852 198,584 164,573 Other income (expense): Interest income .......................................... 3,974 4,269 7,957 8,388 Interest expense ......................................... (8,205) (6,223) (15,107) (12,165) Other, net ............................................... (291) 547 (674) 425 ------------- ------------- ------------- ------------- Income from continuing operations before taxes, minority interest and equity in earnings (losses) of affiliates ...................... 108,835 89,445 190,760 161,221 Income taxes ................................................. (37,135) (30,636) (64,990) (56,106) Minority interest in net income of subsidiaries .............. (7,131) (3,842) (10,381) (6,757) Equity in earnings (losses) of affiliates .................... 908 (528) 2,418 (505) ------------- ------------- ------------- ------------- Income from continuing operations ............................ 65,477 54,439 117,807 97,853 Discontinued operations: Loss from operations of discontinued components (including write-down of long-lived assets of $32.7 million) ............................... -- (32,700) -- (32,560) Income tax benefit ....................................... -- 12,098 -- 12,038 ------------- ------------- ------------- ------------- Loss from discontinued operations ........................ -- (20,602) -- (20,522) ------------- ------------- ------------- ------------- Net income ................................................... $ 65,477 $ 33,837 $ 117,807 $ 77,331 ============= ============= ============= ============= Earnings from continuing operations per share: Basic .................................................... $ 0.73 $ 0.62 $ 1.32 $ 1.11 ============= ============= ============= ============= Diluted .................................................. $ 0.71 $ 0.60 $ 1.28 $ 1.08 ============= ============= ============= ============= Loss from discontinued operations per share: Basic .................................................... $ -- $ (0.24) $ -- $ (0.23) ============= ============= ============= ============= Diluted .................................................. $ -- $ (0.23) $ -- $ (0.22) ============= ============= ============= ============= Earnings per share: Basic .................................................... $ 0.73 $ 0.38 $ 1.32 $ 0.88 ============= ============= ============= ============= Diluted .................................................. $ 0.71 $ 0.37 $ 1.28 $ 0.86 ============= ============= ============= ============= Weighted-average common shares outstanding: Basic .................................................... 89,587 88,390 89,417 88,154 ============= ============= ============= ============= Diluted .................................................. 92,012 90,591 92,212 90,344 ============= ============= ============= =============
5 - more -
HENRY SCHEIN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) June 28, December 29, 2008 2007 ------------- ------------- (unaudited) ASSETS Current assets: Cash and cash equivalents .................................................. $ 271,432 $ 247,590 Available-for-sale securities............................................... 11,925 997 Accounts receivable, net of reserves of $41,472 and $41,315 ................ 731,499 708,307 Inventories, net ........................................................... 693,556 666,786 Deferred income taxes ...................................................... 36,203 32,827 Prepaid expenses and other ................................................. 186,508 192,292 ------------- ------------- Total current assets ............................................... 1,931,123 1,848,799 Property and equipment, net .................................................... 254,110 247,671 Goodwill ....................................................................... 954,203 917,194 Other intangibles, net ......................................................... 191,039 192,420 Investments and other .......................................................... 139,040 107,900 ------------- ------------- Total assets ....................................................... $ 3,469,515 $ 3,313,984 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable ........................................................... $ 453,800 $ 474,009 Bank credit lines .......................................................... 6,207 8,977 Current maturities of long-term debt ....................................... 23,624 24,319 Accrued expenses: Payroll and related ..................................................... 124,213 136,291 Taxes ................................................................... 87,359 73,278 Other ................................................................... 226,615 223,765 ------------- ------------- Total current liabilities .......................................... 921,818 940,639 Long-term debt ................................................................. 424,470 423,274 Deferred income taxes ........................................................... 92,699 80,260 Other liabilities .............................................................. 54,644 53,906 Minority interest .............................................................. 46,816 35,923 Commitments and contingencies Stockholders' equity: Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding ........................................................ -- -- Common stock, $.01 par value, 240,000,000 shares authorized, 89,762,723 outstanding on June 28, 2008 and 89,603,660 outstanding on December 29, 2007 ............................. 898 896 Additional paid-in capital .................................................. 693,133 673,763 Retained earnings ........................................................... 1,103,206 1,005,055 Accumulated other comprehensive income ...................................... 131,831 100,268 ------------- ------------- Total stockholders' equity ......................................... 1,929,068 1,779,982 ------------- ------------- Total liabilities and stockholders' equity ......................... $ 3,469,515 3,313,984 ============= =============
6 - more -
HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Three Months Ended ----------------------------- June 28, June 30, 2008 2007 ------------- ------------- Cash flows from operating activities: Net income ................................................................. $ 65,477 $ 33,837 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization ....................................... 20,270 17,670 Stock-based compensation expense .................................... 6,956 6,608 Impairment from write-down of long-lived assets of discontinued operations ....................................... -- 32,667 Provision for losses on trade and other accounts receivable ......... 1,467 1 Provision for (benefit from) deferred income taxes .................. 448 (11,833) Undistributed (earnings) losses of affiliates ....................... (908) 528 Minority interest in net income of subsidiaries ..................... 7,131 3,842 Other ............................................................... (891) 151 Changes in operating assets and liabilities, net of acquisitions: Accounts receivable ........................................... (23,256) (12,809) Inventories ................................................... 16,023 11,510 Other current assets .......................................... 8,452 (7,413) Accounts payable and accrued expenses ......................... 24,108 39,884 ------------- ------------- Net cash provided by operating activities ...................................... 125,277 114,643 ------------- ------------- Cash flows from investing activities: Purchases of fixed assets ................................................. (9,723) (12,403) Payments for equity investment and business acquisitions, net of cash acquired ................................................... (15,057) (14,391) Purchases of available-for-sale securities ................................ -- (70,501) Proceeds from sales of available-for-sale securities ...................... -- 30,000 Net payments for foreign exchange forward contract settlements ............ (3,048) (7,692) Other ..................................................................... 5,306 653 ------------- ------------- Net cash used in investing activities .......................................... (22,522) (74,334) ------------- ------------- Cash flows from financing activities: Proceeds from issuance of long-term debt .................................. -- 55 Repayments of bank borrowings ............................................. (2,589) (26) Principal payments for long-term debt ..................................... (4,976) (17,468) Proceeds from issuance of stock upon exercise of stock options ............ 5,523 12,929 Payments for repurchases of common stock .................................. (31,647) -- Excess tax benefits related to stock-based compensation ................... 1,244 2,169 Other ..................................................................... (977) (721) ------------- ------------- Net cash used in financing activities .......................................... (33,422) (3,062) ------------- ------------- Net change in cash and cash equivalents ........................................ 69,333 37,247 Effect of exchange rate changes on cash and cash equivalents ................... (937) (732) Cash and cash equivalents, beginning of period ................................. 203,036 154,456 ------------- ------------- Cash and cash equivalents, end of period ....................................... $ 271,432 $ 190,971 ============= ============= Six Months Ended ----------------------------- June 28, June 30, 2008 2007 ------------- ------------- Cash flows from operating activities: Net income ................................................................. $ 117,807 $ 77,331 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization ....................................... 39,708 35,227 Stock-based compensation expense .................................... 16,216 10,725 Impairment from write-down of long-lived assets of discontinued operations ....................................... -- 32,667 Provision for losses on trade and other accounts receivable ......... 2,604 232 Provision for (benefit from) deferred income taxes .................. (2,891) (18,688) Undistributed (earnings) losses of affiliates ....................... (2,418) 505 Minority interest in net income of subsidiaries ..................... 10,381 6,757 Other ............................................................... (1,317) (570) Changes in operating assets and liabilities, net of acquisitions: Accounts receivable ........................................... (6,752) (16,756) Inventories ................................................... (5,064) 15,446 Other current assets .......................................... 10,955 4,469 Accounts payable and accrued expenses ......................... (40,612) (66,604) ------------- ------------- Net cash provided by operating activities ...................................... 138,617 80,741 ------------- ------------- Cash flows from investing activities: Purchases of fixed assets ................................................. (23,466) (21,336) Payments for equity investment and business acquisitions, net of cash acquired ................................................... (23,581) (41,823) Purchases of available-for-sale securities ................................ (35,925) (88,001) Proceeds from sales of available-for-sale securities ...................... 847 48,000 Net payments for foreign exchange forward contract settlements ............ (5,052) (11,613) Other ..................................................................... 4,571 (4,609) ------------- ------------- Net cash used in investing activities .......................................... (82,606) (119,382) ------------- ------------- Cash flows from financing activities: Proceeds from issuance of long-term debt .................................. -- 483 Repayments of bank borrowings ............................................. (6,508) (281) Principal payments for long-term debt ..................................... (5,949) (17,925) Proceeds from issuance of stock upon exercise of stock options ............ 12,695 23,620 Payments for repurchases of common stock .................................. (31,647) (30,689) Excess tax benefits related to stock-based compensation ................... 4,673 8,022 Other ..................................................................... (1,401) (1,457) ------------- ------------- Net cash used in financing activities .......................................... (28,137) (18,227) ------------- ------------- Net change in cash and cash equivalents ........................................ 27,874 (56,868) Effect of exchange rate changes on cash and cash equivalents ................... (4,032) (808) Cash and cash equivalents, beginning of period ................................. 247,590 248,647 ------------- ------------- Cash and cash equivalents, end of period ....................................... $ 271,432 $ 190,971 ============= =============
7 - more -
Exhibit A Henry Schein, Inc. 2008 Second Quarter Sales Growth Rate Summary (unaudited) Q2 2008 over Q2 2007 -------------------- Consolidated Dental Medical International Technology ------------ ----------- ------------ ------------- ------------ Internal Sales Growth 4.0% 7.2% -8.9% 10.9% 1.8% Acquisitions 9.6% 1.5% 0.6% 28.8% 26.8% ------------ ----------- ------------ ------------- ------------ Local Currency Sales Growth 13.6% 8.7% -8.3% 39.7% 28.6% Foreign Currency Exchange 5.0% 1.0% -- 16.0% 0.4% ------------ ----------- ------------ ------------- ------------ Total Sales Growth 18.6% 9.7% -8.3% 55.7% 29.0% ============ =========== ============ ============= ============ Q2 YTD 2008 over Q2 YTD 2007 ---------------------------- Consolidated Dental Medical International Technology ------------ ----------- ------------ ------------- ------------ Internal Sales Growth 3.5% 6.4% -6.7% 8.3% 5.9% Acquisitions 9.3% 1.6% 0.7% 27.7% 26.2% ------------ ----------- ------------ ------------- ------------ Local Currency Sales Growth 12.8% 8.0% -6.0% 36.0% 32.1% Foreign Currency Exchange 4.8% 1.2% -- 14.8% 0.4% ------------ ----------- ------------ ------------- ------------ Total Sales Growth 17.6% 9.2% -6.0% 50.8% 32.5% ============ =========== ============ ============= ============
CONTACTS: Steven Paladino Executive Vice President and Chief Financial Officer steven.paladino@henryschein.com (631) 843-5500 Investors: Neal Goldner Vice President, Investor Relations neal.goldner@henryschein.com (631) 845-2820 Media: Susan Vassallo Vice President, Corporate Communications susan.vassallo@henryschein.com (631) 843-5562 8 ### -----END PRIVACY-ENHANCED MESSAGE-----